Investor Relations

Minimum 15 minutes delayed. Source: LSEG

100K
Customers
34
Countries Worldwide
$4B
2022 Revenue
50
Years in Business

Our Mission

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction – addressing significant unmet societal and medical needs. We aim to build one of the broadest pipelines of pain therapeutics which combined with our management team’s deep expertise in pain biology, clinical translation, and trial execution, positions us to deliver meaningful patient benefit and to change the current treatment paradigm of pain medicines.

Financial Data

Recent Reports

More information is coming soon.

Environmental, Social & Governance

Lorem ipsum dolor sit amet, consectetur adipisicing elit. A ad corporis deserunt exercitationem facere facilis impedit laboriosam quidem saepe sint. A accusantium doloremque dolores ea esse eveniet iusto magni, modi nostrum numquam officia quam quod repudiandae similique sunt tempore veritatis!